Pallarès-Masmitjà, Maria http://orcid.org/0000-0002-7317-7793
Ivančić, Dimitrije
Mir-Pedrol, Júlia http://orcid.org/0000-0001-6104-9260
Jaraba-Wallace, Jessica
Tagliani, Tommaso
Oliva, Baldomero http://orcid.org/0000-0003-0702-0250
Rahmeh, Amal
Sánchez-Mejías, Avencia
Güell, Marc http://orcid.org/0000-0003-4000-7912
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (825825)
"la Caixa" Foundation (CI1800036, CF19-00010)
"la Caixa" Foundation
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (SAF2017-88784-R)
Article History
Received: 30 October 2020
Accepted: 9 November 2021
First Online: 3 December 2021
Competing interests
: A.S.-M., D.I., M.G. and M.P.-M. have filed patent applications on FiCAT technology. Patent applicant: Pompeu Fabra University; application number: PCT/IB2020/055507; status of application: pending; specific aspect of manuscript covered in patent application: this patent application covered the general aspects of DNA binding proteins fused to integrases and transposases. Specifically, Fig. InternalRef removed, Supplementary Fig. InternalRef removed and preliminary data on activity characterization of some of the hyPB mutants included in Fig. InternalRef removed were disclosed in this patent application. A.S.-M. and M.G. are shareholders of Integra Therapeutics, company that licensed FiCAT technology. The remaining authors declare no competing interests.